Skip to main content

Galileo Genomics Raises $CA11.15 Million in Additional Equity Funding

NEW YORK, Jan.7 (GenomeWeb News) - Galileo Genomics has raised $CA11.15 million ($8.66 million) in additional equity funding, the company said today.


The December funding round includes new investor Carnegie Fund II of Stockholm, as well as existing investors HBM BioVentures of Zurich, MVI of Geneva, and Biofund of Helsinki.


This funding is in addition to $CA7.7 million the company raised last February.


Galileo, based in Montreal, plans to use the additional cash to identify genes associated with common and economically important diseases in the Quebec Founder Population using its chromozoom technology. Moreover, it wants to generate revenues from pharmacogenomics contracts.


Galileo focuses on analyzing DNA from the Quebec Founder Population, which it considers ideal for linkage disequilibrium-based genome-wide scans because of its low genetic variability and extensive genetic sharing.


The Scan

Possibly as Transmissible

Officials in the UK say the B.1.617.2 variant of SARS-CoV-2 may be as transmitted as easily as the B.1.1.7 variant that was identified in the UK, New Scientist reports.

Gene Therapy for SCID 'Encouraging'

The Associated Press reports that a gene therapy appears to be effective in treating severe combined immunodeficiency syndrome.

To Watch the Variants

Scientists told US lawmakers that SARS-CoV-2 variants need to be better monitored, the New York Times reports.

Nature Papers Present Nautilus Genome, Tool to Analyze Single-Cell Data, More

In Nature this week: nautilus genome gives peek into its evolution, computational tool to analyze single-cell ATAC-seq data, and more.